摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-(3,5-二甲基吡唑-1-基)-1,2,4,5-四嗪-3-胺 | 139047-73-7

中文名称
6-(3,5-二甲基吡唑-1-基)-1,2,4,5-四嗪-3-胺
中文别名
——
英文名称
6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazin-3-amine
英文别名
3-amino-6-(3,5-dimethylpyrazol-1-yl)-1,2,4,5-tetrazine;3-amino-6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazine;1,2,4,5-Tetrazin-3-amine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-;6-(3,5-dimethylpyrazol-1-yl)-1,2,4,5-tetrazin-3-amine
6-(3,5-二甲基吡唑-1-基)-1,2,4,5-四嗪-3-胺化学式
CAS
139047-73-7
化学式
C7H9N7
mdl
MFCD01926285
分子量
191.195
InChiKey
JXJYVOAONGQISS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    472.2±48.0 °C(Predicted)
  • 密度:
    1.62±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.6
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.285
  • 拓扑面积:
    95.4
  • 氢给体数:
    1
  • 氢受体数:
    6

SDS

SDS:676f8b10cc5cf37f9ad1283488cc7ecc
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-(3,5-二甲基吡唑-1-基)-1,2,4,5-四嗪-3-胺硝酸 作用下, 以70%的产率得到6-(3,5-dimethyl-1H-pyrazol-1-yl)-N-nitro-1,2,4,5-tetrazin-3-amine
    参考文献:
    名称:
    Synthesis and Properties of Alkylnitramino-1,2,4,5-Tetrazines
    摘要:
    The peculiarities of the nitration reaction under acidic conditions were studied for a series of alkylamino-1,2,4,5-tetrazines. It was found that the extent of N,N'-dialkyl-1,2,4,5-tetrazine-3,6-diamine nitration was determined by the concentration of nitric acid and the selection of alkyl substituents at the exocyclic nitrogen atom. A new method was developed for the preparation of unsymmetrically substituted N,N'-dialkyl-1,2,4,5-tetrazine-3,6-diamines from N-nitro derivatives of N-alkyl-1,2,4,5-tetrazin-3-amines.
    DOI:
    10.1007/s10593-014-1448-9
  • 作为产物:
    参考文献:
    名称:
    Coburn, M.D.; Buntain, G.A.; Harris, B.W., Journal of Heterocyclic Chemistry, 1991, vol. 28, # 8, p. 2049 - 2050
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Synthesis and antimycobacterial activity of imidazo[1,2-b][1,2,4,5]tetrazines
    作者:Dmitry A. Maslov、Anna V. Korotina、Kirill V. Shur、Alexey A. Vatlin、Olga B. Bekker、Svetlana G. Tolshchina、Rashida I. Ishmetova、Nina K. Ignatenko、Gennady L. Rusinov、Valery N. Charushin、Valery N. Danilenko
    DOI:10.1016/j.ejmech.2019.05.081
    日期:2019.9
    tuberculosis strains urge the need to develop anti-TB drugs with a novel mechanism of action. We describe synthesis of 22 novel imidazo[1,2-b][1,2,4,5]tetrazine derivatives with different substituents at C(3) and C(6) positions, and their antimycobacterial activity in vitro. 8 compounds show activity as potential serine/threonine protein kinase (STPK) inhibitors in M. smegmatis aphVIII+ test-system, which
    结核病(TB)最近已成为传染病中的主要杀手。具有多种药物和广泛耐药性的结核分枝杆菌菌株促使人们需要开发具有新颖作用机制的抗结核药物。我们描述了22种新型咪唑并[1,2- b ] [1,2,4,5]四嗪衍生物的合成,这些衍生物在C(3)和C(6)位置具有不同的取代基,并在体外具有抗分枝杆菌活性。8种化合物在耻垢分枝杆菌aphVIII +测试系统中显示出作为潜在的丝氨酸/苏氨酸蛋白激酶(STPK)抑制剂的活性,这是此类的特征。5种活性最高的STPK抑制剂中的3种化合物对结核分枝杆菌H37Rv具有显着的最小抑菌浓度1微克/毫升。我们能够获得对4种化合物有抗药性的耻垢分枝杆菌mc2 155突变体,并表明它们与其他药物没有交叉耐药性,但在这4种咪唑并[1,2- b ] [1,2]中具有共同的耐药机制。,4,5]四嗪。化合物3h似乎是最有前途的,结合了预期的STPK抑制剂活性,结核分枝杆菌的最低MIC和耐药突变体出现的频率较低。
  • Photoactive energetic materials
    申请人:LOS ALAMOS NATIONAL SECURITY, LLC.
    公开号:US09902748B2
    公开(公告)日:2018-02-27
    Energetic materials that are photoactive or believed to be photoactive may include a conventional explosive (e.g. PETN, nitroglycerine) derivatized with an energetic UV-absorbing and/or VIS-absorbing chromophore such as 1,2,4,5-tetrazine or 1,3,5-triazine. Absorption of laser light having a suitably chosen wavelength may result in photodissociation, decomposition, and explosive release of energy. These materials may be used as ligands to form complexes. Coordination compounds include such complexes with counterions. Some having the formula M(L)n2+ were synthesized, wherein M is a transition metal and L is a ligand and n is 2 or 3. These may be photoactive upon exposure to a laser light beam having an appropriate wavelength of UV light, near-IR and/or visible light. Photoactive materials also include coordination compounds bearing non-energetic ligands; in this case, the counterion may be an oxidant such as perchlorate.
    具有光活性或被认为具有光活性的活性材料可能包括与能量吸收紫外线和/或可见光色团(如1,2,4,5-四唑或1,3,5-三唑)衍生的传统爆炸物(例如PETN,硝化甘油)。吸收具有适当选择波长的激光光线可能导致光解、分解和爆炸释放能量。这些材料可以用作配体形成配合物。配位化合物包括具有对离子的这些配合物。一些具有M(L)n2+公式的化合物已经合成,其中M是过渡金属,L是配体,n为2或3。这些化合物在暴露于具有适当波长的紫外线、近红外和/或可见光的激光光束时可能具有光活性。光活性材料还包括携带非活性配体的配位化合物;在这种情况下,对离子可能是诸如高氯酸盐之类的氧化剂。
  • Synthesis of monosubstituted 1,2,4,5-tetrazines – 3-amino-1,2,4,5-tetrazines
    作者:Gennady F. Rudakov、Yurii A. Moiseenko、Natal’ya А. Spesivtseva
    DOI:10.1007/s10593-017-2127-4
    日期:2017.6
    The substitution of pyrazolyl moiety in 3-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazine with N-nucleophiles provided a series of highnitrogen tetrazine derivatives, including 2-nitro-1-(1,2,4,5-tetrazin-3-yl)guanidine, N-(1H-tetrazol-5-yl)-1,2,4,5-tetrazin-3-amine, N-(1,2,4,5-tetrazin-3-yl)-1,2,4,5-tetrazin-3-amine, N,N'-di(1,2,4,5-tetrazin-3-yl)-1,2,4,5-tetrazine-3,6-diamine, N-(1,2,4,5-tetrazin-3-yl)-[1
    用N-亲核试剂取代3-(3,5-二甲基-1 H-吡唑-1-基)-1,2,4,5-四嗪中的吡唑基部分,提供了一系列高氮四嗪衍生物,包括2-硝基-1-(1,2,4,5-四嗪-3-基)胍,N-(1 H-四唑-5-基)-1,2,4,5-四嗪-3-胺,N-( 1,2,4,5-四嗪-3-基)-1,2,4,5-四嗪-3-胺,N,N'-二(1,2,4,5-四嗪-3-基) -1,2,4,5-四嗪-3,6-二胺,N-(1,2,4,5-四嗪-3-基)-[1,2,4]三唑[4,3- b ] [1,2,4,5]四嗪-6-胺和三四嗪胺。通过差示扫描量热法评估了这些新化合物的热稳定性,并计算了它们的能量特性。
  • Simple and Efficient Synthesis of Explosive Cocrystals containing 3,5‐Dimethylpyrazol‐1‐yl‐substituted‐1,2,4,5‐tetrazines
    作者:Christopher J. Snyder、David E. Chavez、Gregory H. Imler、Edward F. C. Byrd、Philip W. Leonard、Damon A. Parrish
    DOI:10.1002/chem.201704394
    日期:2017.11.21
    Exploding Crystals! 3,5-Dimethylpyrazol-1-yl-substituted-1,2,4,5-tetrazines readily react with energetic molecules resulting in the formation of new cocrystalline energetic materials. The quick and easy synthesis is facilitated by strong hydrogen-bonding to the dimethylpyrazolyl group and the new materials have lower sensitivities than their parents energetic compounds.
    爆炸的水晶!3,5-二甲基吡唑-1-基-取代的1,2,4,5-四嗪容易与高能分子反应,导致形成新的共晶高能材料。牢固的氢键与二甲基吡唑基之间的氢键促进了快速,简便的合成,新材料的敏感性低于其母体含能化合物。
  • Tetrazine derived mononuclear RuII(acac)2(L) (1), [RuII(bpy)2(L)](ClO4)2 (2) and [RuII(bpy)(L)2](ClO4)2 (3) (L=3-amino-6-(3,5-dimethylpyrazol-1-yl)-1,2,4,5-tetrazine, acac=acetylacetonate, bpy=2,2′-bipyridine): syntheses, structures, spectra and redox properties
    作者:Animesh Nayak、Srikanta Patra、Biprajit Sarkar、Sandeep Ghumaan、Vedavati G. Puranik、Wolfgang Kaim、Goutam Kumar Lahiri
    DOI:10.1016/j.poly.2004.11.019
    日期:2005.1
    Mononuclear ruthenium complexes of tetrazine derived L, RuII(acac)2(L) (1), [RuII(bpy)2(L)](ClO4)2 (2) and [RuII(bpy)(L)2](ClO4)2 (3) (L = 3-amino-6-(3,5-dimethylpyrazol-1-yl)-1,2,4,5-tetrazine, acac = acetylacetonate and bpy = 2,2′-bipyridine) were prepared. The free L exists as a dimeric entity in the solid state via hydrogen bonding interactions involving L and water molecules present in the crystal
    四嗪衍生的L,Ru II(acac)2(L)(1),[Ru II(bpy)2(L)](ClO 4)2(2)和[Ru II(bpy)(L)的单核钌配合物2 ](ClO 4)2(3)(L = 3-氨基-6-(3,5-二甲基吡唑-1-基)-1,2,4,5-四嗪,acac =乙酰丙酮酸酯,bpy = 2,2制备了′-联吡啶。游离的L通过涉及L和晶格中存在的水分子的氢键相互作用以固态形式以二聚体形式存在。1表现出与Ru II的异常牢固的结合配位为吡唑基-N(2.040(2)Å),尤其是四嗪-N(1.913(2)Å)。在Ru III /钌II的耦合1 - 3分别出现在0.28,1.34和1.50 V与SCE。在-1.33(1)处观察到基于四嗪和bpy的还原。-0.55和-1.55 / -1.75 / -1.98(2); -0.47 / -0.78和-1.80 / -2.02 V(3)。1,2和3中显示的每两个MLCT带,对应于dπ(RU
查看更多

同类化合物

酸四嗪 甲四嗪-氨基叔丁酯 四嗪-氨基叔丁酯 嘧啶并[4,5-e]-1,2,3,4-四嗪 二甲基-1,2,4,5-四嗪 二氯均四嗪 METHYLTETRAZINE-ACID,甲基四嗪-羧基 6-苯基-1,2,4,5-四嗪-3-胺 6-乙基-1,2,4,5-四嗪-3-胺 6-丁基氨基-3-(3,5-二甲基吡唑-1-基)四嗪 6-(3,5-二甲基吡唑-1-基)-1,2,4,5-四嗪-3-胺 3,6-二苯基-1,2,4,5-四嗪 3,6-二氨基-1,2-二氢-1,2,4,5-四嗪盐酸盐 3,6-二-4-吡啶基-1,2,4,5-四嗪 3,6-二-2-吡啶基-1,2,4,5-四嗪 3,6-二(噻吩-2-基)-1,2,4,5-四嗪 3,6-二(3-吡啶基)-1,2,4,5-四氮杂苯 3,6-二(3,5-二甲基-1H-吡唑-1-基)-1,2,4,5-四嗪 1-[6-(3,5-二甲基吡唑-1-基)-1,2,4,5-四嗪-3-基]-2-(丙-2-亚基)肼 1,2-二氢-1,2,4,5-四嗪-3,6-二酮 1,2,4,5]四嗪-3,6-二羧酸 1,2,4,5-四嗪-3-胺 1,2,4,5-四嗪-3,6-二羧酸二甲酯 1,2,4,5-四嗪 (9CI)-吡咯并[2,1-d]-1,2,3,5-四嗪 (6-肼基-1,2,4,5-四嗪-3-基)肼 3-(3,5-Dimethyl-1-pyrazolyl)-6-(2-trifluoroacetylhydrazino)-1,2,4,5-tetrazine 3-cyclohexyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine 3-ethyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine 6-pentyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine 3-benzyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine 3-methyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine N'-(6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazin-3-yl)propionohydrazide 3-(2-ethylidenehydrazinyl)-6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazine (1,2,4,5-tetrazine-3,6-diyl)dimethanol 3-amino-6-chloro-1,2,4,5-tetrazine 6-(3,5-dimethyl-1H-pyrazol-1-yl)-N-methyl-1,2,4,5-tetrazin-3-amine N-(tert-butyl)-6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazin-3-amine 6-(3,5-dimethyl-1H-pyrazol-1-yl)-N-(prop-2-en-1-yl)-1,2,4,5-tetrazin-3-amine 3-(2-pyrimidyl)-6-(2-hydroxy)ethyl-1,2,4,5-tetrazine 3-isopropyl-6-phenyl-1,2,4,5-tetrazine 6-butylamino-3-chlorotetrazine 3,6-di(1H-pyrazol-4-yl)-1,2,4,5-tetrazine N-(1H-tetrazol-5-yl)-1,2,4,5-tetrazin-3-amine 3-(3,5-dimethylpyrazolyl)-6-[tris(hydroxylmethyl)aminomethane]-1,2,4,5-tetrazine 2-([1,2,4]triazolo[4,3-b][1,2,4,5]tetrazin-3-ylamino)-2-(hydroxymethyl)propane-1,3-diol 6-amino-1,2,4-triazolo<4,3-b><1,2,4,5>tetrazine N-phenethyl-[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazin-3-amine 2,5-dioxopyrrolidin-1-yl 2-(4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenyl)acetate furazano-1,2,3,4-tetrazine 1,3-dioxide